Encoded Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
341 Oyster Point Blvd Ste 100, South San...Phone Number
(650) 491-0272Website
www.encoded.comRevenue
$37.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
3
1
1
About Encoded Therapeutics
Encoded Therapeutics, Inc. is a biotechnology company developing gene therapies for genetic disorders. The company is headquartered in South San Francisco, California.Explore more
Encoded Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Encoded Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Encoded Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Encoded Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Encoded Therapeutics is spiking on competitors!
Click to see if Encoded Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Encoded Therapeutics has new funding data
Product Launch: Get notified when Encoded Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Encoded Therapeutics
Earning: See what the market has to say on Encoded Therapeutics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Encoded Therapeutics
Compare insights from companies similar to Encoded Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
51-200
Private
$147.5M
2018
RR
Renuka RamanathanVice President Head of Corporate & Business Development
Company Profile Activity
Activity Insights
Encoded Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Encoded Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Encoded Therapeutics.
Encoded Therapeutics Tech Stack
A closer look at the technologies used by Encoded Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Open Position
Encoded Therapeutics News & Media
Encoded Therapeutics to Present New Data for CNS Gene Therapy Programs at the ASGCT 28th Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, today announced three presentations that underscore the strength of the Company’s vector engineering platform and demonstrate continued progress of the ETX201 in Angelman syndrome (AS), chronic pain and Alzheimer’s disease / tauopathies programs. The presentations will be made at the 28th Annual Meeting ofEncoded Therapeutics Reports Clinical Progress of ETX101 Gene Therapy for Dravet Syndrome, Recaps 2024 Corporate Achievements and Provides 2025 Outlook
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, today announced continued progress in its lead clinical program, ETX101, and highlighted corporate achievements that advance its research pipeline and further develop infrastructure to fully integrate the Company’s gene therapy capabilities. “In 2024, we launched our ongoing POLARIS program evaluating ETX1Encoded Demonstrates Therapeutic Potential of a Vectorized miRNA-based Approach for Angelman Syndrome at the FAST Annual Global Science Summit
ORLANDO, Fla.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, announced today that it will present new preclinical data on ETX201, an AAV9-based vectorized miRNA approach designed to reduce the expression of the UBE3A-ATS and unsilence paternal UBE3A expression for the treatment of Angelman syndrome. At the Foundation for Angelman Syndrome Therapeutics (FAST) 17th Annual Global ScEncoded Therapeutics Presents Preclinical Data Across its Gene Therapy Portfolio at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ASGCT2024--Encoded Therapeutics Inc., a biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, today highlights oral and poster presentations on the Company’s preclinical gene therapy programs and vector engineering platform at the 27th ASGCT Annual Meeting being held May 7 – 11, 2024 in Baltimore, MD. “We are thrilled to share multiple advancements across our portfolio of precision genetic medicines,
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Encoded Therapeutics
Sign Up For FreeTo access detailed company insights
Encoded Therapeutics, Inc. is a biotechnology company developing gene therapies for genetic disorders. The company is headquartered in South San Francisco, California.... Read More
